Table 3. Univariate and multivariate Cox proportional hazards analysis of MFN2 expression and OS for patients with colon cancer in the validation cohort.
| Clinicopathologic variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Age | 1.03 | 1.01–1.05 | 0.013 | 1.04 | 1.01–1.06 | 0.001 | |
| Gender | 1.11 | 0.70–1.78 | 0.653 | – | – | – | |
| Stage (AJCC) | 2.34 | 1.78–3.06 | 7.72E−10 | 1.68 | 0.76–3.71 | 0.20 | |
| T | 2.89 | 1.81–4.59 | 7.92E−06 | 1.53 | 0.88–2.67 | 0.13 | |
| M | 4.83 | 2.96–7.87 | 2.65E−10 | 1.36 | 0.47–3.97 | 0.58 | |
| N | 2.02 | 1.54–2.66 | 4.40E−07 | 1.23 | 0.75–2.01 | 0.41 | |
| MFN2 | 0.94 | 0.91–0.98 | 0.001 | 0.95 | 0.92–0.99 | 0.007 | |
AJCC, American Joint Committee on Cancer; Stage-T, the depth of tumor invasion; Stage-N, lymph node metastasis; Stage-M, distant metastasis; MFN2, mitofusin 2; HR, hazard ratio; OS, overall survival; CI, confidence interval.